

# SBE13

Catalog No: tcsc3786



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

775294-82-1

**Formula:**

$C_{24}H_{27}ClN_2O_4$

**Pathway:**

Cell Cycle/DNA Damage;Autophagy

**Target:**

Polo-like Kinase (PLK);Autophagy

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

442.94


## Product Description

SBE13 is a potent and selective **Plk1** inhibitor, with an **IC<sub>50</sub>** of 200 pM; SBE13 poorly inhibits Plk2 (IC<sub>50</sub>>66 μM) or Plk3 (IC<sub>50</sub>=875 nM).

IC50 & Target: IC50: 200 pM (Plk1), >66 μM (Plk2), 875 nM (Plk3)<sup>[1]</sup>

**In Vitro:** SBE13 significantly reduce cell proliferation and induce apoptosis in HeLa cells, with an EC<sub>50</sub> of 18 μM<sup>[1]</sup>. SBE13 (1-100 μM)

shows no effect on Caspase 3/7 activity in NIH-3T3 cells. SBE13 (66 and 100  $\mu$ M) does not change morphology after treatment of primary cells. SBE13 (10 and 100  $\mu$ M) reduces pRb staining in primary cells, and this indicates a G0/G1 arrest<sup>[2]</sup>. SBE13 (66 and 100  $\mu$ M) increases levels of cyclin B1, phospho histone H3, Wee1, Emi1 and securin, and results in cleavage of Cdc27 in HeLa cells. SBE13 (10 and 100  $\mu$ M) also induces apoptosis of HeLa cells<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!